Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010

BMC Medicine

Alison Cooper¹  Julia Verne²  Sarah Mee¹  Anita Mehay¹  Luke Hounsome²  Therese Lloyd¹ 

[1] Evidence Team, Prostate Cancer UK, 4th Floor Counting House, 53 Tooley Street, London, UK;Knowledge and Intelligence Team (South West), Public Health England, 2 Rivergate, Temple Quay, Bristol, UK

关键词: White;    Prostate cancer;    Lifetime risk;    Ethnicity;    Epidemiology;    Black;    Asian;   

Others  :  1221509
DOI  :  10.1186/s12916-015-0405-5

 received in 2015-04-08, accepted in 2015-06-22,  发布年份 2015

【 摘 要 】

Background

In the UK, a man’s lifetime risk of being diagnosed with prostate cancer is 1 in 8. We calculated both the lifetime risk of being diagnosed with and dying from prostate cancer by major ethnic group.

Methods

Public Health England provided prostate cancer incidence and mortality data for England (2008–2010) by major ethnic group. Ethnicity and mortality data were incomplete, requiring various assumptions and adjustments before lifetime risk was calculated using DevCan (percent, range).

Results

The lifetime risk of being diagnosed with prostate cancer is approximately 1 in 8 (13.3 %, 13.2–15.0 %) for White men, 1 in 4 (29.3 %, 23.5–37.2 %) for Black men, and 1 in 13 (7.9 %, 6.3–10.5 %) for Asian men, whereas that of dying from prostate cancer is approximately 1 in 24 (4.2 %, 4.2–4.7 %) for White men, 1 in 12 (8.7 %, 7.6–10.6 %) for Black men, and 1 in 44 (2.3 %, 1.9–3.0 %) for Asian men.

Conclusions

In England, Black men are at twice the risk of being diagnosed with, and dying from, prostate cancer compared to White men. This is an important message to communicate to Black men. White, Black, and Asian men with a prostate cancer diagnosis are all as likely to die from the disease, independent of their ethnicity. Nonetheless, proportionally more Black men are dying from prostate cancer in England.

【 授权许可】

   
2015 Lloyd et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Cancer Research UK. Prostate cancer statistics. 2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/. Accessed 17 Oct 2014.
• [2]Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011; 105:1795-803.
• [3]Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M et al.. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian Men. J Natl Cancer Inst. 2013; 105:1050-8.
• [4]Office for National Statistics. Deaths Registered in England and Wales (Series DR), 2012. 2013. http://www.ons.gov.uk/ons/rel/vsob1/mortality-statistics--deaths-registered-in-england-and-wales--series-dr-/2012/stb-deaths-registered-in-england-and-wales-in-2012-by-cause.html. Accessed 17 Oct 2014.
• [5]National Records of Scotland. Vital Events Reference Tables 2013. Section 6: Deaths - Causes. 2014. http://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/general-publications/vital-events-reference-tables/2013/section-6-deaths-causes. Accessed 17 Oct 2014.
• [6]Northern Ireland Statistics & Research Agency. Registrar General Annual Report 2012 – Section 6.4 Deaths, by sex, age and cause, 2012. 2013. http://www.nisra.gov.uk/archive/demography/publications/annual_reports/2012/Table6.4_2012.xls. Accessed 17 Oct 2014.
• [7]Cancer Research UK. Prostate cancer incidence statistics: By Age (2009–2011). 2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-One. Accessed 19 May 2014.
• [8]Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003; 107:797-803.
• [9]Johns L, Houlston R. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003; 91:789-94.
• [10]Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011; 6: Article ID e27130
• [11]World Cancer Research Fund International. Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. 2014. www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf. Accessed 18 Nov 2014.
• [12]Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. Ecancer medical science. 2014; 8:455.
• [13]Cancer Research UK & National Cancer Intelligence Network. Cancer Incidence and Survival by Major Ethnic Group, England, 2002–2006. 2009. http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_INCSURV_ETHNIC.pdf. Accessed 9 May 2013.
• [14]Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F et al.. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol. 2008; 53:99-105.
• [15]Chinegwundoh F, Enver M, Lee A, Nargund V, Oliver T, Ben-Shlomo Y. Risk and presenting features of prostate cancer amongst African-Caribbean, South Asian and European men in North-East London. BJU Int. 2006; 98:1216-20.
• [16]Jack RH, Davies EA, Møller H. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England. BJU Int. 2010; 105:1226-30.
• [17]Karami S, Young HA, Henson DE. Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev. 2007; 31:29-34.
• [18]Metcalfe C, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F et al.. Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study. Br J Cancer. 2008; 99:1040-5.
• [19]Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008; 123:430-5.
• [20]Evans S, Metcalfe C, Patel B, Ibrahim F, Anson K, Chinegwundoh F et al.. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer. 2010; 102:249-54.
• [21]National Cancer Intelligence Network. Treatment Routes in Prostate Cancer – Urological Cancers SSCRG. 2012. http://www.ncin.org.uk/view?rid=1260. Accessed 14 Jun 2013.
• [22]Public Health England. Prostate cancer and ethnicity. 2013. http://www.ncin.org.uk/view?rid=2635. Accessed 3 May 2014.
• [23]National Cancer Intelligence Network. Mortality from Prostate Cancer – Urological Cancers SSCRG. 2012. http://www.ncin.org.uk/view?rid=1701. Accessed 15 Oct 2013.
• [24]Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK et al.. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008; 40:316-21.
• [25]Eckersberger E, Finkelstein J, Sadri H, Margreiter M, Taneja SS, Lepor H et al.. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol. 2009; 11:127-33.
• [26]Cancer Research UK. Prostate cancer incidence statistics: Lifetime risk (2010). 2012. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Three. Accessed 22 Aug 2013.
• [27]Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Stat Med. 2003; 22:1837-48.
• [28]Fay MP. Estimating age conditional probability of developing disease from surveillance data. Popul Health Metr. 2004; 2:6. BioMed Central Full Text
• [29]National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.0. Statistical Research and Applications Branch. 2013. http://srab.cancer.gov/devcan/. Accessed 18 Mar 2014.
• [30]Cashman RE, Gerhardt PR, Goldberg ID, Handy VH, Levin ML. The probability of developing cancer. J Natl Cancer Inst. 1956; 17:155-73.
• [31]Cancer Research UK and the National Cancer Intelligence Network. Calculating Lifetime Risk. 2013. http://www.cancerresearchuk.org/health-professional/cancerstatistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Three. Accessed 31 Mar 2014.
• [32]Sasieni PD, Shelton J, Ormiston-Smith N, Thomson CS, Silcocks PB. What is the lifetime risk of developing cancer? The effect of adjusting for multiple primaries. Br J Cancer. 2011; 105:460-5.
• [33]Office for National Statistics. 2008 population estimates from ONS Table EE4: Estimated resident population by ethnic group, age and sex, mid-2008 (experimental statistics). 2009. http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population+Estimates+by+Ethnic+Group#tab-data-tables. Accessed 26 Sep 2013.
• [34]Office for National Statistics. 2009 population estimates from ONS Table EE4: Estimated resident population by ethnic group, age and sex, mid-2009 (experimental statistics). 2011. http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population+Estimates+by+Ethnic+Group#tab-data-tables. Accessed 26 Sep 2013.
• [35]Office for National Statistics. 2010 population estimates from 2011 census data: DC2101EW - Ethnic group by sex by age. 2010. http://www.nomisweb.co.uk/census/2011/DC2101EW. Accessed 26 Sep 2013.
• [36]Health & Social Care Information Centre. A Guide to Linked Mortality Data from Hospital Episode Statistics and the Office for National Statistics. 2013. http://www.hscic.gov.uk/media/11668/HES-ONS-Mortality-Data-Guide/pdf/guide_to_linked_ONS_HES_mortality_data_V4_040613.pdf. Accessed 22 May 2014
• [37]World Health Organization. WHO Mortality Data base documentation. 2014. http://www.who.int/entity/healthinfo/statistics/documentation.zip?ua=1. Accessed 5 Sep 2014.
• [38]Office for National Statistics. Population Estimates by Ethnic Group: Important Note on Reliability of Estimates for Subnational Areas. 2011. http://www.ons.gov.uk/ons/rel/peeg/population-estimates-by-ethnic-group--experimental-/current-estimates/peegs-notes-on-reliability-of-estimates.pdf. Accessed 16 Jul 2014.
• [39]Public Health England. Prostate cancer incidence and mortality and all-cause mortality, 2008-2010. Data provided on request by the Knowledge and Intelligence Team (South West), Public Health England. 2014
• [40]Office for National Statistics. Table 1: Registrations of newly diagnosed cases of cancer (3rd digit): site, sex and age, 2008. 2010. Available from: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/no--39--2008/cancer-statistics-registrations-tables--england--series-mb1---2008.zip. Accessed 4 Nov 2013.
• [41]Office for National Statistics. Table 1: Registrations of newly diagnosed cases of cancer (3rd digit): site, sex and age, 2009. 2011. Available from: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/no--40--2009/cancer-registrations-2009.xls. Accessed 4 Nov 2013.
• [42]Office for National Statistics. Table 1: Registrations of newly diagnosed cases of cancer (3rd digit): site, sex and age, 2010. 2012. Available from: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/no--41--2010/rft-cancer-registrations-2010.xls. Accessed 4 Nov 2013.
• [43]Office for National Statistics. VS3 Mortality by cause, England, 2008, 2009 and 2010. Data provided on request. 2014
• [44]NHS Choices. Be Clear on Cancer – Prostate cancer. 2014. http://www.nhs.uk/prostate. Accessed 6 Jan 2015.
• [45]Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst. 2011; 103:1436-43.
• [46]Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al.. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010; 341:c4543.
• [47]Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V et al.. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384:2027-35.
• [48]Cancer Research UK. Prostate cancer incidence statistics: Trends over time, 1975–2011. 2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Two. Accessed 23 Sep 2014.